Tare da taimakon Bioendo, samfurin rigakafin GMP na farko na kasar Sin ya amince da amfani da EU kuma an ƙaddamar da shi a cikin kasuwar EU.

A karshen shekarar 2019, sabuwar annobar kambi ta yi tsanani.A cikin Disamba 2020, sabon maganin rigakafin cutar kambi wanda sanannen kamfani na biopharmaceutical ya samar kuma ya samar da kashi 86% akan kamuwa da kwayar cutar, kuma adadin canza garkuwar jikin mutum ya kasance 99%, wanda zai iya zama rigakafi 100%.lokuta masu tsanani da tsanani na COVID-19.Alurar rigakafin ta sami izinin yin amfani da gaggawa a cikin wata ƙasa a cikin watan Satumba don kare ma'aikatan kiwon lafiya da ke yaƙi a sahun gaba na annobar.Yarjejeniyar magunguna ta ƙasa da hukuma ta ba da takardar shaidar GMP ta EU a hukumance don sabon rigakafin da ba a kunna rawanin ga kamfanin biopharmaceutical.Wannan shi ne samfurin rigakafin farko da aka amince da amfani da shi a cikin EU da GMP da aka tabbatar a tarihin kasar Sin, yana daukar wani sabon mataki don sabon rigakafin kambi na kasar Sin ya zama samfurin jama'a na duniya.Domin da gaske nuna tasirin bushewar zafi mai zafi da lalata layin samar da maganin vial, kamfaninmu yana amfani da tsarin samarwa na musamman don keɓance 2ml, 3ml da sauran ƙayyadaddun ƙayyadaddun nau'ikan kwalban kwalban da aka yi amfani da su wajen samar da biopharmaceutical. kamfani.Babban zafin jiki resistant kwayoyin Endotoxin nuna alama (bushewar zafi haifuwa endotoxin nuna alama ECV), wanda warware samar da bukatun na maganin alurar riga kafi.Kamfaninmu ya yi aikinmu a cikin aiwatar da bincike da haɓaka sabbin rigakafin rigakafin kambi na ƙasa, samarwa, sarrafa inganci, da gano endotoxin.